A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression

References

• Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010; 9:675-84; http://dx.doi.org/10.1593/neo.10688
   Web of Science ®Google Scholar
• Wikstrand CJ, Sampson JH, Bigner DD. EGFRvIII: an oncogene deletion mutant cell surface receptor target expressed by multiple tumour types. Expert Opin Ther Targets 2000; 4:497-514; http://dx.doi.org/10.1517/14728222.4.4.497
   Google Scholar
• Kuan CT, Wikstrand CJ, Bigner DD. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol 2000; 17:71-8; PMID:11210174; http://dx.doi.org/10.1007/BF02482738
   PubMedGoogle Scholar
• Lo HW. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol 2010; 3:37-52; PMID:20030624; http://dx.doi.org/10.2174/1874467211003010037
   PubMedGoogle Scholar
• Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-6; PMID:16943533; http://dx.doi.org/10.1200/JCO.2006.07.2587
   PubMed Web of Science ®Google Scholar
• Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25:2164-70; PMID:17538160; http://dx.doi.org/10.1200/JCO.2006.06.6605
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12:5064-73; PMID:16951222; http://dx.doi.org/10.1158/1078-0432.CCR-06-0913
   PubMed Web of Science ®Google Scholar
• Keller J, Shroyer KR, Batajoo SK, Zhao HL, Dong LM, Hayman MJ, Chan EL. Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer. Cancer Invest 2010; 28:1054-62; PMID:20873989; http://dx.doi.org/10.3109/07357907.2010.512602
   PubMed Web of Science ®Google Scholar
• Chen LF, Cohen EEW, Grandis JR. New Strategies in Head and Neck Cancer: epidermal growth factor receptor inhibition in head and neck cancer. Clin Cancer Res 2010; 16:2489-95; PMID:20406834; http://dx.doi.org/10.1158/1078-0432.CCR-09-2318
   PubMed Web of Science ®Google Scholar
• Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev 2014; 40:567-77; PMID:24216225; http://dx.doi.org/10.1016/j.ctrv.2013.10.002
   PubMed Web of Science ®Google Scholar
• Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets 2012; 12:197-209; PMID:22268382; http://dx.doi.org/10.2174/156800912799277557
   PubMed Web of Science ®Google Scholar
• De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 2010; 12:304-16; PMID:20167819; http://dx.doi.org/10.1093/neuonc/nop068
   PubMed Web of Science ®Google Scholar
• Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19:1389-400; PMID:24202392; http://dx.doi.org/10.1038/nm.3388
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221-37; PMID:17059365; http://dx.doi.org/10.1146/annurev.med.58.070605.115320
   PubMed Web of Science ®Google Scholar
• Shan L, Wang PC. Recombinant immunotoxin therapy of solid tumors: challenges and strategies. J Basic Clin Med 2013; 2:1-6; PMID:25309827
   PubMedGoogle Scholar
• Schmidt M Vakalopoulou E, Schneider DW, Wels W. Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor. Br J Cancer 1997; 75:1575-84; PMID:9184171; http://dx.doi.org/10.1038/bjc.1997.270
   PubMed Web of Science ®Google Scholar
• Ochiai H, Archer GE, Herndon JE 2nd, Kuan CT, Mitchell DA, Bigner DD, Pastan IH, Sampson JH. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother 2008; 57:115-21; PMID:17634939; http://dx.doi.org/10.1007/s00262-007-0363-7
   PubMed Web of Science ®Google Scholar
• Chandramohan V, Bigner DD. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. Oncoimmunol 2013; 2:e26852; http://dx.doi.org/10.4161/onci.26852
   Google Scholar
• Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 2013; 19:4717-27; PMID:23857604; http://dx.doi.org/10.1158/1078-0432.CCR-12-3891
   PubMed Web of Science ®Google Scholar
• Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, Groner B, Wels W. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 2000; 86:269-75; PMID:10738256; http://dx.doi.org/10.1002/(SICI)1097-0215(20000415)86:2%3c269::AID-IJC18%3e3.0.CO;2-8
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003; 65:27-35; PMID:14649883; http://dx.doi.org/10.1023/A:1026290315809
   PubMed Web of Science ®Google Scholar
• Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, et al. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br J Cancer 2005; 92:1069-77; PMID:15770208; http://dx.doi.org/10.1038/sj.bjc.6602470
   PubMed Web of Science ®Google Scholar
• Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001; 61:5355-61; PMID:11454674
   PubMed Web of Science ®Google Scholar
• Johns TG, Mellman I, Cartwright GA, Ritter G, Old LJ, Burgess AW, Scott AM. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J 2005; 19:780-2; PMID:15774576
   PubMed Web of Science ®Google Scholar
• Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim YS, Rothacker J, Nice EC, Walker F, et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004; 279:30375-84; PMID:15075331; http://dx.doi.org/10.1074/jbc.M401218200
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007; 104:4071-6; PMID:17360479; http://dx.doi.org/10.1073/pnas.0611693104
   PubMed Web of Science ®Google Scholar
• Woo JH, Liu YY, Stavrou S, Neville DM. Increasing secretion of bivalent anti-T-cell immunotoxin by Pichia pastoris. Appl Environ Microbiol 2004; 70:3370-6; PMID:15184133; http://dx.doi.org/10.1128/AEM.70.6.3370-3376.2004
   PubMed Web of Science ®Google Scholar
• Kim GB, Wang Z, Liu YY, Stavrou S, Mathias A, Goodwin KJ, Thomas JM, Neville DM. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin. Protein Eng Des Sel 2007; 20:425-32; PMID:17693455; http://dx.doi.org/10.1093/protein/gzm040
   PubMed Web of Science ®Google Scholar
• Zhang F, Shan L, Liu Y, Neville D, Woo JH, Chen Y, Korotcov A, Lin S, Huang S, Sridhar R, et al. An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy. Adv Healthc Mater 2013; 2:736-44; PMID:23184611; http://dx.doi.org/10.1002/adhm.201200254
   PubMed Web of Science ®Google Scholar
• Liu YY, Woo JH, Neville DM. Overexpression of an anti-CD3 immunotoxin increases expression and secretion of molecular chaperone BiP/Kar2p by Pichia pastoris. Appl Environ Microbiol 2005; 71:5332-40; PMID:16151122; http://dx.doi.org/10.1128/AEM.71.9.5332-5340.2005
   PubMed Web of Science ®Google Scholar
• Hauser BR, Zhu X, Califano J, Gu X. Detection of gene copy number of epidermal growth factor receptor in head and neck squamous cell carcinomas cell lines. Cancer Res 2008; 68: 3413; PMID:18451169; http://dx.doi.org/10.1158/0008-5472.CAN-07-1919
   PubMed Web of Science ®Google Scholar
• Hauser BR. Epidermal growth factor receptor (EGFR) gene expression and its related biomarkers in head and neck squamous cell carcinoma [master's thesis]. [Washington DC]: Howard University; 2008. 58 p.
   Google Scholar
• Liu YY, Woo JH, Neville DM. Targeted introduction of a diphtheria toxin resistant mutation into the chromosomal EF-2 locus of Pichia pastoris and expression of immunotoxin in the EF-2 mutants. Protein Expr Purif 2003; 30:262-74; PMID:12880776; http://dx.doi.org/10.1016/S1046-5928(03)00129-3
   PubMed Web of Science ®Google Scholar
• Li YM, Vallera DA, Hall WA. Diphtheria toxin-based targeted toxin therapy for brain tumors. J Neurooncol 2013; 114:155-64; PMID:23695514; http://dx.doi.org/10.1007/s11060-013-1157-8
   PubMed Web of Science ®Google Scholar
• Adkins I, Holubova J, Kosova M, Sadilkova L. Bacteria and their toxins tamed for immunotherapy. Curr Pharm Biotechnol 2012; 13:1446-73; PMID:22339216; http://dx.doi.org/10.2174/138920112800784835
   PubMed Web of Science ®Google Scholar
• Matar AJ, Pathiraja V, Wang Z, Duran-Struuck R, Gusha A, Crepeau R, Tasaki M, Sachs DH, Huang CA. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment. Transpl Immunol 2012; 27:52-4; PMID:22676970; http://dx.doi.org/10.1016/j.trim.2012.05.003
   PubMed Web of Science ®Google Scholar
• Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 2009; 9:1445-51; PMID:19817678; http://dx.doi.org/10.1517/14712590903348135
   PubMed Web of Science ®Google Scholar
• Woo JH, Liu JS, Kang SH, Singh R, Park SK, Su Y, Ortiz J, Neville DM, Willingham MC, Frankel AE. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1), for phase I/II clinical trials. Protein Expr Purif 2008; 58:1-11; PMID:18160309; http://dx.doi.org/10.1016/j.pep.2007.11.006
   PubMed Web of Science ®Google Scholar
• Bühler P, Wetterauer D, Gierschner D, Wetterauer U, Beile UE, Wolf P. Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer. Anticancer Res 2010; 30:3373-9; PMID:20944111
   PubMed Web of Science ®Google Scholar
• Thompson J, Stavrou S, Weetall M, Hexham JM, Digan ME, Wang Z, Woo JH, Yu Y, Mathias A, Liu YY, et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng 2001; 14:1035-41; PMID:11809934; http://dx.doi.org/10.1093/protein/14.12.1035
   PubMedGoogle Scholar
• Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56:5079-86; PMID:8895767
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91:7727-31; PMID:8052651; http://dx.doi.org/10.1073/pnas.91.16.7727
   PubMed Web of Science ®Google Scholar
• Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24:1731-45; PMID:20713517; http://dx.doi.org/10.1101/gad.1890510
   PubMed Web of Science ®Google Scholar